For response rates, it’s a tricky question to answer, but Table 7 in the below provides an overview from a range of studies. There’s a few complicating factors, including what counts as a response (stable disease? Shrinkage?), and inclusion of targeted therapies (Bevacizumab, cetuximab). As a rough figure though I think you’d be reasonable to take a number in the order of about 60% (possibly higher if you include stable disease, and/or targeted therapies).https://onlinelibrary.wiley.com/doi/ful ... ags3.12071
This study showed a wide range of response rates of 40% and almost 80%, again depending on measurement criteria used:https://www.ajronline.org/doi/10.2214/AJR.11.7910
My situation was similar to yours - I was lucky to be resectable at diagnosis but still did 6 rounds of FOLFOX before liver resection; scans before surgery had good shrinkage, and pathology after surgery showed tumour necrosis ranging 40-80%.
I was also told that CEA taken during chemo is not particularly meaningful.
Best of luck.
Male 38; Australia
10/2018 Dx 3.5cm RC adenocarcinoma, 12cm from AV
Mod diff, EMVI+ LVI+. 4 liver mets
pT3N1aM1a; Stage IVa. MSS, NRAS (G13R)
CEA: Oct-18= 12; Nov-18= 14, Mar-19= 2.4, Aug-19 <2.0, Mar-20=2.2, May-20=1.9.
11/18 FOLFOX x6
3/19 Liver resection
5/19 25x pelvic VMAT radiation; complete metabolic response
07/19 ULAR (robot), temp ileo, 1/27 LN
08/19 Missed a liver spot
08-11/19 FOLFOX x1, FOLFOXIRI x1, FOLFIRI x5
12/19 Liver resection #2
02/20 Ileostomy reversed
03/20 PET & MRI = NED!